Circular RNAs as Prognostic Biomarkers in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Dan Liao1†, Qiu Lin1, Huan Xiao2, Fenglian Zhang1 and Qin Han3†

1Department of Nephrology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China, 2Department of Radiology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China, 3School of Public Health, Chengdu Medical College, Chengdu, China

Background: Recently, several studies have shown that circRNAs play critical roles in renal cell carcinoma (RCC) oncogenesis and development. However, whether the level of circRNA expression in RCC is correlated with prognosis remains unclear. Hence, we conducted a meta-analysis to explore the association between circRNA expression levels and the prognosis of RCC patients.

Methods: We systematically searched Ovid, Embase, PubMed, and Web of Science from January 1950 to June 2021 for the literature published in English. According to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines, we conducted a meta-analysis of 21 selected studies to confirm the association between the circRNA expression level and prognosis of RCC.

Results: This meta-analysis included 20 articles and 1,559 RCC patients. The results showed that the high expression of oncogenic circRNAs (OS: HR = 2.04, 95% CI: 1.63–2.56, p = 0.20; PFS: HR = 2.82, 95% CI: 0.82–9.72, p = 0.03) and low expression of tumor-suppressor circRNAs (OS: HR: 1.92, 95% CI: 1.61–2.30, p < 0.05; PFS: HR: 2.40, 95% CI: 1.76–3.28, p = 0.36) were closely related to poor survival outcomes.

Conclusion: The meta-analysis verifies that circRNAs can be potential prognostic biomarkers of RCC.

Keywords: circular RNAs, renal cell carcinoma, prognostic biomarkers, systematic review, meta-analysis

INTRODUCTION

Worldwide, kidney cancer has become a serious and widespread prevalent problem and is the 16th most frequently diagnosed cancer with the 17th highest mortality, accounting for 2.2% of all oncological diagnoses and 1.8% of all oncological deaths (Capitanio et al., 2019; Sung et al., 2021). Renal cell carcinoma (RCC) is a common cancer that originates in the renal epithelium and accounts for 90% of kidney cancers (Hsiieh et al., 2017). Although the diagnosis and treatment (immunotherapy (Xu et al., 2020), targeted agents (Yang and Chen, 2020), and combination...
therapy (Cerbone et al., 2020)) of RCC have improved in the last 20 years, the overall survival of patients with RCC is still less than satisfactory (Haddad and Margulis, 2015; Xu et al., 2020). To guide clinical decision-making, a great prognostic evaluation of RCC is urgently necessary for both physicians and patients in treatment management. Currently, aside from imaging examination, reliable biomarkers that can be applied in clinical practice are lacking. Overall, more sensitive prognostic biomarkers and more effective therapeutic strategies for cancer need to be found.

CircRNAs are characterized by covalently closed-loop structures with neither 5′-3′ polarity nor polyadenylated tails (Chen and Yang, 2015). CircRNAs were identified as critical molecules in transcriptional regulation, splicing alternatives, interactions with RNA-binding proteins, and microRNA sponges in cellular physiology and disease pathogenesis (Han et al., 2018). CircRNAs have been confirmed as regulators and biomarkers for numerous types of cancers, which can act as either oncogenic or tumor suppressors in cancer and have also been shown to be enriched and stable in extracellular fluid (Chen and Huang, 2018). These findings indicate the potential of circRNAs to be effective biomarkers. Furthermore, as previously reported, circRNAs have a critical role in promoting metastasis in RCC (Yang et al., 2021). CircRNAs can contribute to tumorigenesis in RCC and promote proliferation and differentiation of RCC by regulating tumor-related signaling pathways (Li et al., 2020a) and activating transcription factors (Chen et al., 2020a). Thus, we reasonably predict that circRNAs may be potential effective therapeutic targets. In addition, many studies have identified that different expression levels of circRNAs are associated with survival in RCC patients. We therefore performed a meta-analysis to evaluate the prognostic value of circRNAs in RCC.

**MATERIALS AND METHODS**

**Literature Search**

We searched the English medical literature in PubMed, Ovid, Embase, and Web of Science to identify all publications on circRNAs as prognostic biomarkers in human renal cell carcinoma. The database surveys were conducted on June 4, 2021. The following keywords were used in the database search: (“Circular RNA” and “Renal Cell Cancer”) (the detailed search terms are listed in Supplementary Table S1). We eliminated all irrelevant literature works by scanning the article title and abstract. We excluded all duplicated publications by using EndNote X9. The selected studies were identified after they were read in full by our reviewers.

**Publication Inclusion and Exclusion Criteria**

The two investigators (DL and QH) independently used the same multistep process to evaluate whether these studies were suitable for our meta-analysis. A third investigator (QL) resolved any disagreements. The inclusion criteria for meta-analysis followed the population, intervention, control, and outcome (PICO) criteria: 1) patients with a pathological diagnosis of RCC, 2) the expression of circRNAs in the tissue specimens of patients was measured, and 3) the included studies provided time-to-event data, including overall survival (OS), progression-free survival (PFS), recurrence-free survival (RFS), disease-free survival (DFS), and association with circRNA expression. Considering the similar survival outcomes, RFS and DFS were combined as PFS (Zhou et al., 2015).

Furthermore, the excluded articles were eliminated based on the following criteria: 1) the publications that were not published in English; 2) letters, reviews, expert opinions, case reports, conference articles, clinical guidelines, and meeting records; 3) studies of patient sample size <30; 4) duplicated studies; 5) studies of cell lines or animals; and 6) the survival data shown in the article were not sufficient to calculate the HR value.

**Data Extraction**

The two investigators (DL and HX) independently extracted relevant data for meta-analysis, and a third investigator (FZ) resolved any disagreements. Finally, we extracted the following items: the first author’s name, publication year, publication journal, circRNA type, total number of patients, sex, country, and follow-up period. The prognostic endpoints included hazard ratios (HRs) and 95% confidence intervals (CIs), OS, DFS, RFS, and PFS. With only the survival curve provided, Engauge Digitizer version 12.1 (available at http://sourceforge.net/) was used to extract related data from the survival curve. According to the extracted data and method of Spotswood et al. (Spruance et al., 2004), the HR was calculated.

**Quality Assessment**

Two researchers (DL and QH) independently assessed the quality of all selected studies according to the Newcastle–Ottawa Scale (NOS) method (Stang, 2010). The two investigators identified all differences through discussion and consensus. Studies with NOS scores ranging from zero to normal and NOS scores ≥ six were considered high quality.

**Statistical Analysis**

Meta-analysis was performed using a meta package (V.4.18–2). To determine heterogeneity between several studies, we used the $I^2$ test and the chi-based Q-test to assess statistical heterogeneity. If $I^2$ was equal to or <50%, the heterogeneity between studies was not obvious, so we used a fixed-effect model and instead applied the random-effect model (Borenstein et al., 2010). Finally, publication bias was evaluated with a funnel plot (a two-sided $p < 0.05$ was considered to be statistically significant). All statistical analyses were carried out in R V.3.6.1 (R Foundation for Statistical Computing). $p \leq 0.05$ was considered to be statistically significant.

**RESULTS**

**Research Results**

Detailed information on the literature search is shown in **Figure 1**. A total of 77 publications in English were initially retrieved from the database. The most recent publication date was...
June 2021. In total, thirty-three articles were directly excluded after examining the abstract and title. For the remaining 34 publications, after careful reading, 14 studies were eliminated for the following reasons: eight were not associated with circRNAs or RCC, two were animal experiments, and four had insufficient data for analysis. A total of 21 studies were chosen for the meta-analysis based upon the inclusion and exclusion criteria.

**Study Characteristics and Quality Assessment**

Of the 20 publications identified, 1,559 RCC patients were included, and the average number of patients was 77.95 (range 90.5–193.5). The main characteristics of the 10 studies are summarized in Table 1. One study was from Germany, two studies were from The Cancer Genome Atlas (TCGA) database, and other studies were from China. Together, 20 types of circRNAs were included in the meta-analysis (circHIAT1 (Wang et al., 2017; Wang et al., 2019), circNUP98 (Yu et al., 2019), circMYLK (Li et al., 2020a), hsa_circ_001895 (Chen et al., 2020a), circ-EGLN3 (Lin and Cai, 2020), circ_001842 (Zeng et al., 2020), circ_0001368 (Chen et al., 2020b), cRAPGEF5 (Chen et al., 2020c), circ-ABCB10 (Huang et al., 2019), circCSNK1G3 (Li et al., 2021), circAKT1 (Zhu et al., 2020), circAGAP1 (Lv et al., 2021), circ_101341 (Yue et al., 2020), circEHD2 (Frey et al., 2021), circNETO2 (Frey et al., 2021), ciRS-7 (Zhao et al., 2020), hsa-hsa_circ_0085576 (Liu et al., 2020a), circTLK1 (Li et al., 2020b), circPTCH1 (Liu et al., 2020b), and circHIPK3 (Han et al., 2020)). Four circRNAs (circHIAT1, circ_0001368, cRAPGEF5, and circEHD2) were downregulated, and 16 circRNAs (circMYLK, hsa_circ_001895, circ-ABCB10, circAGAP1, circEHD2, hsa_circ_0085576, circTLK1, circPTCH1, circHIPK3, circNUP98, circ-EGLN3, circ_001842, circCSNK1G3, circAKT1, and circ_101341) were upregulated.

The NOS for quality evaluation of the included studies varied from 6 to 8, indicating that all included studies were available and were high-quality studies. Among the 20 identified articles, NOS assessment included 4 documents with an NOS score of 6, 6 articles with an NOS score of 7, and 10 articles with an NOS score of 8. The value of the k-statistic was 0.87, indicating excellent agreement between the two reviewers. Therefore, all 20 eligible studies underwent meta-analysis (Table 2).

The Relationship Between circRNA Expression and Survival Outcomes

**The Relationship Between circRNA Expression and OS**
The meta-analysis defined OS as the primary endpoint. Among the 20 publications, all studies verified the relationship between
### Table 1: Characteristics of the included studies.

| Study             | Year | circRNA     | No. of patients | Outcome | Expression regulation | Median OS | HR       | Country | Multivariate analysis | Indirect |
|-------------------|------|-------------|-----------------|---------|-----------------------|-----------|----------|---------|-----------------------|----------|
| Kefeng Wang       | 2017 | circHAT1    | 40              | OS      | Downregulation        | Low vs. high | 3.75     | China   | No                    | Yes      |
| Rui Yu            | 2020 | circNUP98   | 65              | OS      | Upregulation          | Low vs. high | 0.48     | China   | No                    | Yes      |
| Rui Yu            | 2020 | circNUP98   | 65              | DFS     | Upregulation          | Low vs. high | 0.52     | China   | No                    | Yes      |
| Jianfa Li         | 2020 | circMYLK    | 71              | OS      | Upregulation          | Low vs. high | 1.25     | China   | No                    | Yes      |
| Zhuangfi Chen     | 2019 | hsa_circ_001895 | 60       | OS      | Downregulation        | Low vs. high | 0.63     | China   | No                    | Yes      |
| Zhengmin Wang     | 2019 | circHAT1    | 80              | OS      | Downregulation        | Low vs. high | 1.90     | China   | No                    | Yes      |
| Ling Lin          | 2019 | circ-EGLN3  | 80              | OS      | Downregulation        | Low vs. high | 0.59     | China   | No                    | Yes      |
| Jiawei Zeng       | 2020 | circ_001842 | 97              | OS      | Upregulation          | Low vs. high | 0.37     | China   | No                    | Yes      |
| Lin Chen          | 2020 | circ_0001368| 64              | OS      | Downregulation        | Low vs. high | 1.92     | China   | Yes No                | No       |
| Qiong Chen        | 2020 | cRAPGEFS5   | 245             | OS      | Downregulation        | Low vs. high | 1.79     | China   | Yes No                | No       |
| Qiong Chen        | 2020 | cRAPGEFS5   | 245             | RFS     | Downregulation        | Low vs. high | 1.64     | China   | Yes No                | No       |
| Yunfang Huang     | 2021 | Circ-ABCB10 | 120             | OS      | Upregulation          | High vs. low | 5.29     | China   | Yes No                | No       |
| Wei Li            | 2020 | circCSNK1G3 | 64              | OS      | Downregulation        | Low vs. high | 0.34     | TCGA-KICH | Yes No                | No       |
| Qingliang Zhu     | 2021 | CircAKT1    | 70              | OS      | Downregulation        | Low vs. high | 0.56     | China   | No Yes                | No       |
| Qi Lv             | 2021 | CircAGAP1   |                 | OS      | Upregulation          | High vs. low | 1.68     | TCGA-KICH | No No                | No       |
| Yongjun Yue       | 2020 | Circ_101341 | 60              | OS      | Upregulation          | High vs. low | 0.42     | China   | No                    | Yes      |
| Lisa Frey         | 2021 | circEHD2    | 121             | PFS     | Downregulation        | High vs. low | 3.58     | Germany | Yes No                | No       |
| Lisa Frey         | 2021 | circNETO2   | 121             | PFS     | Downregulation        | High vs. low | 0.17     | Germany | Yes No                | No       |
| Lisa Frey         | 2021 | circEHD2    | 121             | CSS     | Downregulation        | High vs. low | 2.67     | Germany | Yes No                | No       |
| Lisa Frey         | 2021 | circNETO2   | 121             | CSS     | Downregulation        | High vs. low | 0.14     | Germany | Yes No                | No       |
| Lisa Frey         | 2021 | circEHD2    | 121             | OS      | Downregulation        | High vs. low | 3.91     | Germany | Yes No                | No       |
| Yanhui Zhao       | 2020 | cirPS-7     | 87              | PFS     | Downregulation        | High vs. low | 0.53     | China   | No Yes                | No       |
| Guanghua Liu      | 2020 | has-         | 86              | OS      | Upregulation          | High vs. low | 1.37     | China   | No Yes                | No       |
| Guanghua Liu      | 2020 | has-         | 86              | DFS     | Downregulation        | High vs. low | 2.14     | China   | No Yes                | No       |
| Jianfa Li         | 2020 | CircTLK1    | 60              | OS      | Upregulation          | Low vs. high | 0.45     | China   | No                    | Yes      |
| Jianfa Li         | 2020 | CircTLK1    | 60              | DFS     | Upregulation          | Low vs. high | 0.86     | China   | No                    | Yes      |
| Huan Liu          | 2020 | circPTCH1   | 39              | OS      | Downregulation        | Low vs. high | 0.65     | China   | No Yes                | No       |
| Bin Han           | 2020 | CircHIP3    | 50              | OS      | Downregulation        | Low vs. high | 0.42     | China   | No Yes                | No       |

*PS: indirect: we indirectly calculated HR from the plot; multivariate analysis: multivariate analysis was used to adjust HR.*

### Table 2: Quality assessment was based on the Newcastle–Ottawa Scale (NOS).

| First author       | Year | Selection | Comparability | Outcome | Total score |
|--------------------|------|-----------|---------------|---------|-------------|
| Wang et al. (2017) | 2017 | 4         | 2             | 1       | 7           |
| Yu et al. (2020)   | 2020 | 3         | 2             | 1       | 6           |
| Li et al. (2020a)  | 2020 | 4         | 2             | 1       | 7           |
| Chen et al. (2020a)| 2019 | 4         | 2             | 2       | 8           |
| Wang et al. (2019)| 2019 | 3         | 2             | 2       | 7           |
| Lin and Cai (2020)| 2019 | 4         | 1             | 1       | 6           |
| Zeng et al. (2020)| 2020 | 4         | 2             | 1       | 7           |
| Chen et al. (2020b)| 2020 | 4         | 2             | 2       | 8           |
| Chen et al. (2020c)| 2020 | 3         | 2             | 2       | 7           |
| Huang et al. (2019)| 2019 | 4         | 1             | 1       | 6           |
| Li et al. (2021)   | 2020 | 3         | 2             | 2       | 7           |
| Zhu et al. (2020)  | 2020 | 4         | 2             | 2       | 8           |
| Lv et al. (2021)   | 2021 | 4         | 2             | 2       | 8           |
| Yue et al. (2020)  | 2020 | 3         | 1             | 2       | 6           |
| Frey et al. (2021) | 2021 | 4         | 1             | 1       | 6           |
| Zhao et al. (2020) | 2020 | 4         | 2             | 2       | 8           |
| Liu et al. (2020a) | 2020 | 3         | 2             | 2       | 7           |
| Li et al. (2020b)  | 2020 | 4         | 2             | 1       | 7           |
| Liu et al. (2020b) | 2020 | 4         | 1             | 2       | 7           |
| Han et al. (2020)  | 2020 | 4         | 2             | 2       | 8           |
FIGURE 2 | Forest plots verify the association between the expression of circRNAs and overall survival (OS). High expression of oncogenic circRNAs and low expression of tumor-suppressor circRNAs were associated with poor OS.

| Study            | TE   | seTE | Hazard Ratio | HR    | 95% CI          | Weight (fixed) | Weight (random) |
|------------------|------|------|--------------|-------|-----------------|----------------|-----------------|
| regulation = down-regulation |      |      |              |       |                 |                |                 |
| Keleng Wang      | 1.32 | 0.5849 | 3.75 [1.19; 11.80] | 1.5%  | 1.5%            |                |                 |
| Zhengmiao Wang   | 0.64 | 0.2639 | 1.90 [1.13; 3.19] | 7.4%  | 7.4%            |                |                 |
| Lin Chen         | 0.65 | 0.1597 | 1.92 [1.41; 2.63] | 20.1% | 20.1%           |                |                 |
| Qiong Chen       | 0.58 | 0.2576 | 1.79 [1.08; 2.97] | 7.7%  | 7.7%            |                |                 |
| Lisa Frey        | 1.90 | 0.5661 | 6.67 [2.20; 20.22] | 1.6%  | 1.6%            |                |                 |
| Fixed effect model |    |      |              |       |                 | 2.04 [1.63; 2.58] | 38.3%          |
| Random effects model |    |      |              |       |                 | 2.15 [1.57; 2.94] | 38.3%          |
| Heterogeneity: $I^2 = 32\%$, $t^2 = 0.0400$, $p = 0.20$ |      |      |              |       |                 |                |                 |

FIGURE 3 | Forest plots verify the association between the expression of circRNAs and progression-free survival (PFS). High expression of oncogenic circRNAs and low expression of tumor-suppressor circRNAs were associated with poor PFS.

| Study            | TE   | seTE | Hazard Ratio | HR    | 95% CI          | Weight (fixed) | Weight (random) |
|------------------|------|------|--------------|-------|-----------------|----------------|-----------------|
| regulation = up-regulation |      |      |              |       |                 |                |                 |
| Jianfa Li        | -0.22| 0.6623 | 0.80 [0.22; 2.93] | 1.2%  | 1.2%            |                |                 |
| Zhuangfei Chen   | 0.46 | 0.3942 | 1.59 [0.73; 3.44] | 3.3%  | 3.3%            |                |                 |
| Yunfang Huang    | 1.67 | 0.6367 | 5.29 [1.52; 18.42] | 1.3%  | 1.3%            |                |                 |
| Qi Lv            | 0.52 | 0.1597 | 1.68 [1.23; 2.30] | 20.1% | 20.1%           |                |                 |
| Lisa Frey        | 1.36 | 0.5127 | 3.91 [1.45; 10.68] | 2.0%  | 2.0%            |                |                 |
| Guanghua Liu     | 0.32 | 0.3992 | 1.37 [0.63; 3.00] | 3.2%  | 3.2%            |                |                 |
| Jianfa Li        | 0.80 | 0.4731 | 2.22 [0.88; 5.62] | 2.3%  | 2.3%            |                |                 |
| Huan Liu         | 0.43 | 1.5185 | 1.54 [0.08; 30.17] | 0.2%  | 0.2%            |                |                 |
| Bin Han          | 0.87 | 0.4964 | 2.98 [0.90; 9.30] | 2.1%  | 2.1%            |                |                 |
| Rui Yu           | 0.73 | 0.2620 | 2.08 [1.25; 3.48] | 7.5%  | 7.5%            |                |                 |
| Ling Lin         | 0.53 | 0.3196 | 1.69 [0.91; 3.17] | 5.0%  | 5.0%            |                |                 |
| Jiawei Zeng      | 0.99 | 0.3399 | 2.70 [1.39; 5.26] | 4.4%  | 4.4%            |                |                 |
| Wen Li           | 1.08 | 0.9024 | 2.94 [0.50; 17.23] | 0.6%  | 0.6%            |                |                 |
| Qingliang Zhu    | 0.56 | 0.3196 | 1.79 [0.95; 3.34] | 5.0%  | 5.0%            |                |                 |
| Yongjun Yue      | 0.87 | 0.3808 | 2.38 [1.13; 5.02] | 3.5%  | 3.5%            |                |                 |
| Fixed effect model |    |      |              |       |                 | 1.92 [1.61; 2.30] | 61.7%          |
| Random effects model |    |      |              |       |                 | 1.92 [1.61; 2.30] | 61.7%          |
| Heterogeneity: $I^2 = 0\%$, $t^2 = 0$, $p = 0.76$ |      |      |              |       |                 |                |                 |

| Study            | TE   | seTE | Hazard Ratio | HR    | 95% CI          | Weight (fixed) | Weight (random) |
|------------------|------|------|--------------|-------|-----------------|----------------|-----------------|
| regulation = up-regulation |      |      |              |       |                 |                |                 |
| Lisa Frey        | 1.28 | 0.4908 | 3.58 [1.97; 9.37] | 6.5%  | 6.5%            |                |                 |
| Yanhui Zhao      | 0.83 | 0.4432 | 1.89 [0.79; 4.50] | 9.0%  | 9.0%            |                |                 |
| Guanghua Liu     | 0.76 | 0.3507 | 2.14 [1.08; 4.26] | 12.7% | 12.7%           |                |                 |
| Jianfa Li        | 0.15 | 0.6261 | 1.16 [0.34; 3.97] | 4.0%  | 4.0%            |                |                 |
| Rui Yu           | 0.65 | 0.3054 | 1.92 [1.06; 3.50] | 16.7% | 16.7%           |                |                 |
| Wen Li           | 1.41 | 0.3424 | 4.10 [2.13; 7.89] | 14.0% | 14.0%           |                |                 |
| Fixed effect model |    |      |              |       |                 | 2.40 [1.76; 3.28] | 61.5%          |
| Random effects model |    |      |              |       |                 | 2.23 [1.74; 2.84] | 100.0%         |
| Heterogeneity: $I^2 = 9\%$, $t^2 = 0.0157$, $p = 0.36$ |      |      |              |       |                 |                |                 |

FIGURE 3 | Forest plots verify the association between the expression of circRNAs and progression-free survival (PFS). High expression of oncogenic circRNAs and low expression of tumor-suppressor circRNAs were associated with poor PFS.
OS and circRNA expression levels (Supplementary Table S2). As shown in Figure 2, because of the few heterogeneities among the included studies (OS: downregulation: $I^2 = 32\%$, $p = 0.2$; upregulation: $I^2 = 0\%$, $p = 0.75$), the pooled HR and corresponding 95% CI were estimated by applying the fixed-effect model. Overall, the results demonstrated that the differential expression of circRNAs is closely related to poor survival in RCC ($HR = 1.97$, 95% CI: $1.71$–$2.27$, $p < 0.0001$). The results indicated that patients with oncogenic circRNA overexpression had worse OS than those with low expression (OS: $HR = 2.04$, 95% CI: $1.63$–$2.56$, $p < 0.0001$). Furthermore, the results demonstrated that the lower expression of some tumor-suppressor circRNAs was associated with poor OS ($HR: 1.92$, 95% CI: $1.61$–$2.30$, $p < 0.0001$) (Figure 2).

**The Relationship Between circRNA Expression and PFS**

Among the included studies, PFS was reported in three studies, RFS was reported in one study, and DFS was reported in four studies (Supplementary Table S3). Considering the similar survival outcomes, RFS and DFS were combined as PFS. As shown in Figure 3, there were large heterogeneities ($I^2 = 79\%$, $p = 0.03$) in the downregulation group and a few heterogeneities ($I^2 = 9\%$, $p = 0.36$) in the upregulation group. A random effect model was applied in the downregulation group, and a fixed effect model was applied in the upregulation group. The results also demonstrated that the oncogenic circRNA overexpression was associated with worse PFS than low expression (PFS: $HR = 2.82$, 95% CI: $1.82$–$9.72$, $p < 0.0001$), and lower expression of tumor-suppressor circRNAs was correlated with poor PFS (HR: $2.40$, 95% CI: $1.76$–$3.28$, $p = 0.0009$) (Figure 3).

**Meta-Regression**

Meta-regression was performed based on OS. We performed the univariate meta-regression and multivariate meta-regression to further assess the heterogeneity (Table 3). The results revealed that plot and country of multivariate analysis may significantly influence the variation in HR (univariate meta-regression: $p$-value for year = 0.659, $p$-value for expression regulation = 0.682, $p$-value for indirect = 0.768, $p$-value for multivariate analysis = 0.531, and $p$-value for country; multivariate meta-regression: $p$-value for year = 0.611, $p$-value for regulation = 0.966, $p$-value for indirect = 0.019, $p$-value for multivariate analysis = 0.013, and $p$-value for country = 0.016).

**Publication Bias**

Publication bias analysis was performed based on OS, as shown in Figure 4, and the funnel plot was approximately symmetrical. Publication bias was also assessed by Begg’s and Egger’s tests in the meta-analysis. The results (Begg’s $p = 0.0693$ and Egger’s $p = 0.0798$) and funnel plot all indicated no obvious publication bias among the included studies.

### TABLE 3 | Meta-regression analysis of the included studies.

| Factor  | Univariate meta-regression p-value | Multivariate meta-regression analysis p-value |
|---------|-----------------------------------|---------------------------------------------|
| Year    | 0.659                             | 0.611                                       |
| Regulation | 0.682                   | 0.966                                       |
| Direct vs. Indirect | 0.768      | 0.019                                       |
| Multi   | 0.531                             | 0.013                                       |
| Country | 0.912                             | 0.016                                       |

| 95% CI            | 95% CI            |
|-------------------|-------------------|
| $-0.2339$ to $0.1479$ | $-0.4241$ to $0.2485$ |
| $-0.3491$ to $0.9419$ | $-0.4696$ to $0.4413$ |
| $-0.2401$ to $0.3293$ | $0.1613$ to $1.8256$ |
| $-0.1982$ to $0.3861$ | $0.2048$ to $1.7720$ |
| $-0.3458$ to $0.3087$ | $-1.7281$ to $-0.1788$ |

PS: 1) Year: publication year; 2) Regulation: upregulation vs. downregulation; 3) Direct: extract HR from the manuscript, indirect: calculate HR from the plot; 4) Multivariate analysis: multivariate analysis was used to adjust HR; 5) Country: China vs. TCGA or Germany.
**DISCUSSION**

RCC is characterized by both high mortality and morbidity (Jonasch et al., 2014). Metastasis and recurrence are some of the leading causes of death. Therefore, more accurate biomarkers are needed for predicting the prognosis of RCC patients to monitor the patient’s condition. Here, we summarized the prognostic value of circRNAs in RCC. This meta-analysis, including 21 studies and 1,559 RCC patients, is the first to investigate the relationship between circRNAs and the prognosis of RCC patients. According to the included studies, we found that oncogenic circRNAs with high expression and tumor-suppressor circRNAs with lower expression were correlated with worse survival, which indicated that circRNAs may play important roles in tumor initiation and progression.

CircRNAs play both oncogenic and tumor-suppressor roles in RCC (Yang et al., 2021). CircRNAs function predominantly by acting as sponges of microRNAs. In this way, circRNAs can regulate tumor-related signaling pathways. Li et al. (2020a) found that circular RNA hsa_circ_0072309 can play an antitumor role by sponging miR-513a-5p/VEGFC signaling. Furthermore, Zhang et al. also found that circular RNA hsa_circ_0054537 can regulate the cMet pathway to promote the progression of RCC by sponging miR-130a-3p (Li et al., 2020c). In addition to its oncogenic role, Chen et al. (2019) also found that circular RNA hsa-circ-0072309 can play an antitumor role by deactivating the PI3K/AKT and mTOR pathways by sponging miR-100. Sun et al. (2020) found that circUBAP2 can regulate the miR-148a-3p/FOX2 pathway to inhibit the proliferation and metastasis of RCC. Furthermore, circRNAs can also regulate transcription factors to impact tumor initiation and evolution. For example, circular RNA hsa_circ_001895 regulates SRY-box transcription factor 12 (SOX12) by sponging microRNA-296-5p to promote RCC progression (Chen et al., 2020a). These studies indicate that circRNAs play an important role in tumorigenesis, tumor development, and metastasis, which demonstrates that circRNAs have the potential to act as biomarkers for the prognosis of RCC.

However, we tried to ensure the authenticity and reliability of the meta-analysis. Nonetheless, there are still some limitations in this research. Only 1,559 RCC patients were included, and all samples were from China and Germany, which also leads to publication bias. Thus, more studies performed in other parts of the world are needed. Furthermore, because some HR values were not reported in the article, HR was calculated by Kaplan/Meier curves in some studies lacking HR values. Subjective factors may be introduced. Future studies investigating the relationship between the expression of circRNAs and prognosis in RCC need to provide more complete data.

In summary, we performed a meta-analysis to identify the prognostic value of circRNAs in RCC patients. The results demonstrate that the high expression of circRNAs with cancer-promoting effects and the low expression of circRNAs with tumor-suppressing effects are associated with poor prognosis in RCC patients. Furthermore, many circRNAs play significant roles in RCC initiation and progression. Future studies utilizing circRNAs may demonstrate an effective prognostic biomarker in all RCC patients.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Materials; further inquiries can be directed to the corresponding author.

**AUTHOR CONTRIBUTIONS**

Conceptualization: QH, DL, and QL; methodology: DL, QL, and HX; validation: FZ, QH, and QL; data curation: DL, QL, HX, and FZ; writing—original draft preparation: DL, QH, and HX; writing—review and editing: DL, QL, HX, and FZ; visualization: DL, QL, and QH; supervision: DL and QH; project administration: QL, FZ, and QH; funding acquisition: DL and QH. All authors have read and agreed to the published version of the manuscript.

**FUNDING**

This research was funded by the Special Fund for Hypertension, Sichuan Medical Association (No. 2019TG26).

**ACKNOWLEDGMENTS**

The authors would like to thank all of the patients, investigators, and staff involved in the included studies.

**REFERENCES**

Borenstein, M., Hedges, L. V., Higgins, J. P. T., and Rothstein, H. R. (2010). A Basic Introduction to Fixed-Effect and Random-Effects Models for Meta-Analysis. Res. Synth. Method 1 (2), 97–111. doi:10.1002/jrsm.12

Capitanio, U., Bensalah, K., Bex, A., Boorjian, S. A., Bray, F., Coleman, J., et al. (2019). Epidemiology of Renal Cell Carcinoma. Eur. Urol. 75 (1), 74–84. doi:10.1016/j.euro.2018.08.036

Cerbone, L., Cattrini, C., Vallome, G., Latocco, M. M., Boccardo, F., and Zanardi, E. (2020). Combination Therapy in Metastatic Renal Cell Carcinoma: Back to the Future? Seminars Oncol. 47 (6), 361–366. doi:10.1053/j.seminoncol.2020.10.003

Chen, B., and Huang, S. (2018). Circular RNA: An Emerging Non-coding RNA as a Regulator and Biomarker in Cancer. Cancer Lett. 418, 41–50. doi:10.1016/j.canlet.2018.01.011

Chen, L., Wu, D., and Ding, T. (2020). Circular RNA Circ_0001368 Inhibited Growth and Invasion in Renal Cell Carcinoma by Sponging miR-492 and Targeting LATS2. Gene 753, 144781. doi:10.1016/j.gene.2020.144781
Haddad, A. Q., and Margulis, V. (2015). Tumour and Patient Factors in Renal Cell Carcinoma. Frontiers in Genetics | www.frontiersin.org June 2022 | Volume 13 | Article 878700

Chen, Q., Liu, T., Bao, Y., Zhao, T., Wang, J., Wang, H., et al. (2020). CircRNA cRAPGEF5 Inhibits the Growth and Metastasis of Renal Cell Carcinoma via the miR-27a-3p/TNNIP Pathway. Cancer Lett. 469, 68–77. doi: 10.1016/j.canlet.2019.10.017

Chen, T., Shao, S., Li, W., Liu, Y., and Cao, Y. (2019). RETRACTED ARTICLE: The Circular RNA Hsa-circ_0072309 Plays Anti-tumour Roles by Sponging miR-100 through the Deactivation of PI3K/AKT and mTOR Pathways in the Renal Carcinoma Cell Lines. Artif. Cells, Nanomedicine, Biotechnol. 47 (1), 3638–3648. doi:10.1080/21691401.2019.1657873

Chen, Z., Xiao, K., Chen, S., Huang, Z., Ye, Y., and Chen, T. (2020). Circular RNA Hsa_circ_0018895 Serves as a Sponge of microRNA-296-5p to Promote Clear Cell Renal Cell Carcinoma Progression by Regulating SOX12. Cancer Sci. 111 (2), 713–726. doi:10.1111/cas.14261

Frey, L., Klümpen, N., Schmidt, D., Kristiansen, G., Toma, M., Ritter, M., et al. (2021). CircEHD3. CircNETO2 and CircEGLN3 as Diagnostic and Prognostic Biomarkers for Patients with Renal Cell Carcinoma. Cancers 13 (9), 2177. doi:10.3390/cancers13092177

Han, B., Chao, J., and Yao, H. (2018). Circular RNA and its Mechanisms in Disease: From the Bench to the Clinic. Pharmacol. Ther. 187, 31–44. doi:10.1016/j.pharmthera.2018.01.010

Han, B., Shaolong, E., Luan, L., Li, N., and Liu, X. (2020). CircHIPK3 Promotes Clear Cell Renal Cell Carcinoma (ccRCC) Cells Proliferation and Metastasis via Altering of miR-508-3p/CXCL13 Signal. Oncol. 13, 6051–6062. doi:10.2147/OTT.S251436

Huang, Y., Zhang, Y., Jia, L., Liu, C., and Xu, F. (2019). Circular RNA ABCB10 Promotes Tumor Progression and Correlates with Pejorative Prognosis in Clear Cell Renal Cell Carcinoma. Seminars Nephrol. 40 (1), 86–97. doi:10.1016/j.semnephrol.2019.12.010

Liao, J.-G., Tian, X., Wang, X., Tian, J.-H., Wang, Y., Wang, F., et al. (2015). CircHIPK3 Plays an Oncogenic Role in Renal Cell Carcinoma Progression and Metastasis via Regulating miR-195-5p/29a-3p/29c-3p/CDC42 Signals. Cancer Lett. 394, 1–12. doi:10.1016/j.canlet.2016.12.036

Liu, G., Zhou, J., Piao, Y., Chen, C.-H. (2020). Potential New Therapeutic Approaches for Renal Cell Carcinoma. Seminars Nephrol. 40 (1), 76. doi:10.1111/semnephrol.2019.12.010

Sun, J., Yin, A., Zhang, W., Lv, J., Liang, Y., Li, H., et al. (2020). CircUBAP2 Inhibits Proliferation and Metastasis of Clear Cell Renal Cell Carcinoma via Targeting miR-148a-3p/FoxK2 Pathway. Cell. Transpl. 29, 0963897720925755. doi:10.1177/0963897720925751

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 71 (3), 209–249. doi:10.3322/caac.21660

Wang, K., Sun, Y., Tao, W., Xu, X., and Chang, C. (2017). Androgen Receptor (AR) Promotes Clear Cell Renal Cell Carcinoma (ccRCC) Migration and Invasion via Altering the circH1AT1/miR-195-5p-29a-3p-29c-3p/CDC42 Signals. Cancer Lett. 394, 1–12. doi:10.1016/j.canlet.2016.12.036

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Liao, Lin, Xiao, Zhang and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the original publisher are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.